Nintedanib 150 Bid [clinicaltrials_resource:NCT00514683/group/O5]
Patients were treated with 150mg nintedanib twice daily
group [clinicaltrials_vocabulary:group]
NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/00d2859350382313e6a706a623a6307f]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/048891d20af6461a86d8fe87a2caaf9c]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/0ab56bb779c858031437e75a3625338f]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/0f6c192af285136a9e8474d61485f212]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/12dcc5252ee48945e4e30bb1fa7287f3]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/19d3dd80db1e9f81dd03ea0af088ac68]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/1e873b6778efa982a1715c1ad544c410]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/2404de210b7c429f8720e8b5ec8a17f8]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/244bedfd932ddb4263cfdffb75f3205f]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/269099eab5068fdc56d9ea64dea6199e]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/297cb285392ae5a8f3dbfd91c4fdb9e4]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/323b6000cf9b08c0a729c027e2f46526]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/3dc46fb4b933446d18602d0b67c82874]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/43951924cb09e975e817bf73f512c7d1]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/479a5d9a30d18b63305c31363a0a62a2]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/50cf7c469e96c413b068bff36b8567b1]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/579f9804e6dcaa6d2a1349a2a61e2b67]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/659a2c095915133beb8bc21343a42a81]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/65f3576c96bb48d1962c149016c0211f]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/678386205f89babece9d815907938b33]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/6d9d0bda60b13537ed2c542525e09fd4]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/77171718a06bfdb3447cd8f159832e6f]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/77c438a780a88d64b00b12b5d1bd73d6]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/82a730c03bf052dcffabb797246b7ae7]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/88b308c569128e0e96c4135f458f959b]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/88e247bae1e3a34c754c7c9573866106]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/8c1ad78fd27a35c5e6fb5fbfc950f9d9]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/8c2acc9e3c3f01046526d9fd4ce0c1cc]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/90b91e9dafe50d026678a02d90dbf4aa]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/98d441b7c616c171b6ee8fab4b1d323e]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/9c0926bc717cd1b5d9f116732a6329e9]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/a0dd95802633b834ec7c80c8f1b9af32]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/a1db10e795d9e3f5731789947253bcd5]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/a3f64ad3d369036f302f541e0f59fa57]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/aa6d66b814897cdb3e91125b8b9d0595]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/b000b4642b936d4fd5bd7defc3acacc0]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/bccf946d294369632501f82b0d37e622]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/c0b39b8b428782f9543aebd3383ea568]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/c74df7a1a72508e01125356e5cc2512e]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/c9d2f670096f0a03a1e95a506d93b31b]
group id [clinicaltrials_vocabulary:group-id]
Nintedanib 150 Bid [clinicaltrials_resource:NCT00514683/group/O5]
Patients were treated with 150mg nintedanib twice daily
Bio2RDF identifier
NCT00514683/group/O5
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00514683/group/O5
group id [clinicaltrials_vocabulary:group-id]
description
Patients were treated with 150mg nintedanib twice daily
@en
identifier
clinicaltrials_resource:NCT00514683/group/O5
title
Nintedanib 150 Bid
@en
type
label
Nintedanib 150 Bid [clinicaltrials_resource:NCT00514683/group/O5]
@en